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WepresentacaseofapatientwithHIV/AIDSwhopresentedwithatenderleftlowerextremitycutaneousmassoverasiteofprevious
cryptococcal infectionandwasfoundtohaveplasmablasticlymphoma(PBL).TheincidenceofPBLisestimatedtoaccountforless
than5%ofallcasesofnon-Hodgkinlymphoma(NHL)inHIV-positiveindividuals.Infact,therewereonlytworeportsofextraoral
P B La tt h et i m eo fa2 0 0 3r e v i e w .P B Li nH I V - p o s i t i v ei n d i v i d u a l sis an aggressive malignancy that tends to occur in middle-aged
males with low CD4 counts, high viral loads, and chronic HIV infection. The definitive diagnosis can be made with biopsy which
typically shows malignant lymphoid cells that stain positive for plasma cell markers and negative for B-cell markers. The most
common treatment is chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like
regimens,buttheoverallsurvivalrateispoordespiteitsrelativeresponsivenesstochemotherapy.Thiscasehighlightsthechallenges
that remain in improving clinical outcomes, the importance of antiretroviral therapy and HIV disease control, and a potential
associationbetweenachronicinflammatorystatecausedbydisseminatedCryptococcusandtumorigenesisinindividualswithPBL.
1. Introduction
Kaposi’ssarcoma,non-Hodgkinlymphoma(NHL),andinva-
sive cervical carcinoma are among the three AIDS-defining
malignancies, and, of these, Kaposi’s sarcoma and AIDS-
related non-Hodgkin lymphoma are the most common [1].
AIDS-related NHL can be categorized into systemic NHL,
primary CNS lymphoma, and primary effusion lymphoma
[2]. In HIV-infected individuals, systemic NHL is the most
commonandcanbefurtherdividedintosubtypessuchasdif-
fuselargeB-celllymphoma(DLBCL),Burkitt’slymphoma,T-
cell lymphoma, and plasmablastic lymphoma (PBL), to name
af e w[ 2]. Others have described plasmablastic lymphoma
as a unique variant of DLBCL with a propensity to develop
in HIV-positive patients with frequent involvement of the
oral cavity [3–5]. At the time of a 2003 review, there were
only 2 reports of extraoral plasmablastic lymphoma [4]. Of
the NHL subtypes seen in HIV-positive individuals, the inci-
dence of DLBCL is estimated to account for almost 50% of
the cases while the incidence of plasmablastic lymphoma is
estimated to account for less than 5% of the cases [3, 4].
The median age of presentation for PBL is 38 years with a
greaterpredominanceinmales[5].PBLalsotendstooccurin
HIV-positive individuals with absolute CD4 counts less than
200CMM, mean viral loads greater than 80,000 copies/mL,
and an average duration of HIV infection of 5 years [5]. We
present a rare case of a 63-year-old HIV-positive male who
was found to have plasmablastic lymphoma on biopsy of a
tender left lower extremity cutaneous mass occurring over a
previous site of cryptococcal infection.
2. Case Report
A 63-year-old male with a history of HIV/AIDS (last known
CD4countof279CMM)anddisseminatedCryptococcuspre-
sentedtotheemergencydepartmentwithapainfulprotuber-
ant left lower extremity cutaneous mass. He initially experi-
enced symptoms of bilateral lower extremity lesions four
months prior to presentation, during which surgical biopsy
of a left lateral calf mass yielded necrotizing granulomatous2 Case Reports in Oncological Medicine
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Figure 1: Physical exam of the right thigh revealed two fluctuant, well-circumscribed, circular lesions approximately 3cm in diameter that
were tender to palpation and non-mobile (a). Examination of the left lower extremity showed a fleshy-appearing, pinkish, ovular exophytic
mass approximately 5cm in diameter that was tender to palpation (b) and (c).
inflammation with Cryptococcus.D u r i n gt h a ta d m i s s i o n ,
he was treated with amphotericin and flucytosine and dis-
charged home on oral fluconazole. These cutaneous lesions
persistedandhewastreatedwithperiodicincisionanddrain-
age of these areas; however, this new lesion on his left lower
extremityappearedoverseveralweekspriortothisadmission
and brought him to the emergency room. His physical exam
wasremarkableforthefollowingskinfindings:(1)theantero-
lateral aspect of his right thigh had two fluctuant, well-cir-
cumscribed, circular lesions approximately 3cm in diameter
that were tender to palpation and nonmobile and (2) his
left lower extremity had a fleshy-appearing, pinkish, ovular
exophytic mass approximately 5cm in diameter that was
tender to palpation and appeared to be growing over an area
of previous Cryptococcus infection (Figure 1).
His laboratories showed a repeat absolute CD4 count of
93CMM, HIV RNA PCR of 117copies/mL, and CBC signi-
ficant for a normocytic, normochromic anemia (with an oth-
erwiseunremarkabledifferential).Giventhedifferentappear-
ance of his new left lower extremity lesion, a repeat biopsy
was performed. The biopsy of the cutaneous lesion revealed
sheets of large cells with an abundant amount of cytoplasm
with plasmacytoid features and increased mitosis (Figure 2).
Insomeareas,therewasanincreasednumberoftingiblebody
macrophages noted. Immunohistochemical analysis identi-
fied malignant lymphoid cells that expressed CD138, CD79a,
OCT-2, BOB-1, and MUM-1 with high mitotic rate as noted
by Ki67, while the lymphoma cells were negative for CD20,
CD30, and HHV-8. A cMYC rearrangement was detected
b yF I S H .F l o wc y t o m e t r i ca n a l y s i sa l s os u p p o r t e dt h ev i r t u a l
absence of B-cell markers in the tumor cells. These findings
were consistent with plasmablastic lymphoma. A bone mar-
row biopsy was performed which was negative for any bone
marrow involvement, and a staging CT scan showed a pul-
monary nodule identified in the left lower lobe which is 1.8 ×
1.8cm in diameter (Figure 3), a left perirectal soft tissue mass
2.0 × 2.2cm in diameter (Figure 4), and a focal area of left
analwallthickening2.4×1.6cmindiameter.Furtherbiopsies
were not pursued, and the patient was subsequently started
on his first cycle of cyclophosphamide, doxorubicin, vin-
cristine,andprednisone(CHOP).Thepatientwasrecovering
from his first cycle and awaiting his second cycle of CHOP at
the time of this report.
3. Discussion
Cutaneous plasmablastic lymphoma is a unique presentation
o fa na l r e a d yv e r yr a r ea n da g g r e s s i v es u b t y p eo fn o n -
HodgkinlymphomainHIV-positiveindividuals.Theclinical
presentation of plasmablastic lymphoma, being a subtype of
NHL, can be characterized by the presence of adenopathy
in virtually any location, B symptoms such as fever, night
sweats, weight loss, or anorexia, and extranodal involvement
withsymptomsduetomasseffectofextranodaldisease[6,7].
However, the primary site of presentation of plasmablastic
lymphoma can vary tremendously. The first cases of reportedCase Reports in Oncological Medicine 3
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Figure2:Cutaneousbiopsyrevealedadiffusesheetofsubepidermallargelymphomacellswithhighmitoticrateandoccasionaltingiblebody
macrophages (a) and (b). Immunohistochemical staining showed expression of CD138 (c) and EBV in situ hybridization (EBER transcript)
revealed many of the lymphoma cells infected by EBV (d).
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Figure 3: Staging CT scan showed a pulmonary nodule identified
in the left lower lobe which is 1.8 × 1 . 8c mi nd i a m e t e r .
PBL occurred as oral lesions in HIV-positive patients in the
mid 90s [4]. A review of 112 cases of PBL reported that the
most common primary lymphoma site was the oral cavity
followed by extranodal, nonoral sites such as the nasal and
paranasalcavities,skin,analcanal,softtissues,boneandbone
marrow, CNS, mediastinum, and gonads [5]. The next most
commonsitewasthenonoralandnonanalcomponentsofthe
GI tract, and the least common were the lymph nodes [5]. A
majorityofthecasesofPBLpresentasadvanceddisease(51%
R
P
Figure 4: Staging CT scan showed a left perirectal soft tissue mass
which is 2.0 × 2 . 2c mi nd i a m e t e r .
of cases with Ann Arbor stage III or IV) while 49% of cases
present with stage I or II disease [7].
Like other NHL subtypes, the definitive diagnosis of
plasmablastic lymphoma is made with biopsy of the involved
site. The histopathologicfeatures of PBL include the presence
of a high grade lymphoma comprised of plasmablasts that
stain positive for plasma cell markers such as CD38, VS38c,
MUM1, and CD138 [5] .P B Li sa l s oa s s o c i a t e dw i t hE B V -
positivity, the presence of c-MYC rearrangement, and high4 Case Reports in Oncological Medicine
Ki67expression[5,7,8].PBLisalsocharacterizedbyfrequent
absence of B-cell markers such as CD20 and absence of
HHV8 positivity [5].
With respect to pathogenesis, PBL has been predomi-
nately associated with HIV infection, particularly in indi-
viduals with low absolute CD4 counts, high viral loads, and
chronic HIV infection [5]. However, cases of PBL in the
absence of HIV infection have also been described in associ-
ation with solid organ transplantation and chronic immuno-
suppression and autoimmune disease such as Crohn’s disease
[9]. In addition, latent Epstein-Barr virus (EBV) infection is
detectedinamajority(70%)ofPBLcases[9].Theassociation
between PBL and cryptococcal infection, however, is poorly
s t u d i e da n dl i m i t e dt oaf e wc a s er e p o r t s[ 10, 11].
Given its aggressive nature, a majority of patients with
P B La r et r e a t e dw i t hc h e m o t h e r a p yw i t ht h em o s tc o m m o n
chemotherapeutic regimen being cyclophosphamide, doxo-
rubicin,vincristine,andprednisone(CHOP)[7].Onereview
reports that 23% of cases were treated with more inten-
sive regimens such as HyperCVAD, CODOX-M/IVAC, and
EPOCH, 19% were treated with radiotherapy, 10% were
treated with intrathecal methotrexate, and 27% were treated
with other therapies [7]. R-CHOP appears to be of benefit in
a small subset of HIV-positive individuals with CD20-posi-
tivity, absolute CD4 counts >100CMM, or positive MYC
rearrangements[7]. There is no reported difference in overall
survival between CHOP and more intensive regimens [7].
Theoverallresponseratetochemotherapyisrelativelyhighat
77%with46%ofcasesexperiencingacompleteresponse,31%
w i t hap a r t i a lr e s p o n s e ,a n d2 3 %w i t hn or e s p o n s e[ 7]. How-
ever, despite its responsiveness to chemotherapy, plasma-
blasticlymphomacarriesapoorprognosiswitha5-yearover-
allsurvivalrateof31%andamedianoverallsurvivalperiodof
14 months,with mostcases havingdied due to progressionof
disease [7]. Positive prognostic indicators include early stage
of disease, complete response to chemotherapy, lack of bone
marrow involvement, and use of antiretroviral therapy while
presence of MYC rearrangement is a negative prognostic
indicator [7].
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